These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 35037771)
1. Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma. Bardaro F; Stirpe E J Oncol Pharm Pract; 2022 Jun; 28(4):989-994. PubMed ID: 35037771 [TBL] [Abstract][Full Text] [Related]
2. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. Schiefer M; Hendriks LEL; Dinh T; Lalji U; Dingemans AC Eur J Cancer; 2018 Mar; 91():92-98. PubMed ID: 29413968 [TBL] [Abstract][Full Text] [Related]
3. Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer. Byun JY; Han S; Qdaisat A; Park C Expert Opin Drug Saf; 2024 Aug; 23(8):1007-1015. PubMed ID: 38088244 [TBL] [Abstract][Full Text] [Related]
4. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related]
5. Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC). Watanabe H; Ichihara E; Kano H; Ninomiya K; Tanimoto M; Kiura K Intern Med; 2017 Aug; 56(16):2195-2197. PubMed ID: 28781309 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial. Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885 [TBL] [Abstract][Full Text] [Related]
7. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. Bollinger MK; Agnew AS; Mascara GP J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936 [TBL] [Abstract][Full Text] [Related]
8. [A Case of Significant Ejection Fraction Reduction and Heart Failure Induced by Osimertinib]. Ito S; Otsuka A; Ishii H; Nishihira R; Hirai Y; Nagasawa R; Inoue R; Chin K; Kaneko T Gan To Kagaku Ryoho; 2020 Apr; 47(4):609-613. PubMed ID: 32389962 [TBL] [Abstract][Full Text] [Related]
9. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the Furuta H; Uemura T; Yoshida T; Kobara M; Yamaguchi T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Sakao Y; Yatabe Y; Hida T Anticancer Res; 2018 Sep; 38(9):5231-5237. PubMed ID: 30194172 [TBL] [Abstract][Full Text] [Related]
11. Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature. Sato I; Mizuno H; Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Tani N; Ogura Y; Hirose K; Takeda T Medicina (Kaunas); 2020 Aug; 56(8):. PubMed ID: 32796633 [TBL] [Abstract][Full Text] [Related]
12. Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review. Zhang Q; Liu H; Yang J Front Endocrinol (Lausanne); 2022; 13():833929. PubMed ID: 35677717 [TBL] [Abstract][Full Text] [Related]
13. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report. Zhou Y; Qi X; Wang Y; Dong H; Zhuang L Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042 [TBL] [Abstract][Full Text] [Related]
14. Overall Survival with Osimertinib in Untreated, Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC; N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012 [TBL] [Abstract][Full Text] [Related]
15. Osimertinib induced cardiomyopathy: A case report. Shinomiya S; Kaira K; Yamaguchi O; Ishikawa K; Kagamu H Medicine (Baltimore); 2020 Sep; 99(39):e22301. PubMed ID: 32991436 [TBL] [Abstract][Full Text] [Related]
16. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163 [TBL] [Abstract][Full Text] [Related]
17. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). Anand K; Ensor J; Trachtenberg B; Bernicker EH JACC CardioOncol; 2019 Dec; 1(2):172-178. PubMed ID: 34396179 [TBL] [Abstract][Full Text] [Related]
18. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS; N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359 [TBL] [Abstract][Full Text] [Related]
19. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441 [TBL] [Abstract][Full Text] [Related]
20. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]